Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
MedTech Earnings in the Age of Ozempic May Not Be That Bad
02:01pm, Tuesday, 17'th Oct 2023
September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B
12:01pm, Tuesday, 17'th Oct 2023
Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
07:33pm, Monday, 16'th Oct 2023
Novo Nordisk (NVO) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day.
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
04:43pm, Monday, 16'th Oct 2023
It may be time to eat, drink and buy the dip in food and beverage stocks. Shares of Coca-Cola (NYSE: KO ), Pepsi (NASDAQ: PEP ) and several other sugary drink and snack companies have been pummeled la
Novo Nordisk buys blood pressure treatment to bolster diabtetes portfolio
10:44am, Monday, 16'th Oct 2023
Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a blood pressure drug for with potential applications in cardiovascular and kidney disease, the Danish group said today. Buoyed by the success of
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
10:32am, Monday, 16'th Oct 2023
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal
10:12am, Monday, 16'th Oct 2023
The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.
Novo Nordisk Buys Hypertension Drug in $1.3 Billion Deal
09:50am, Monday, 16'th Oct 2023
Novo Nordisk (NVO) agreed to buy ocedurenone, a drug that treats uncontrolled hypertension and has the potential to be used in cases of cardiovascular and kidney disease, from KBP Biosciences for up t
Novo Nordisk in $1.3 bln deal to buy hypertension drug
07:12am, Monday, 16'th Oct 2023
Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danis
Novo Nordisk to buy hypertension treatment from for $1.3 billion from KBP Biosciences
07:11am, Monday, 16'th Oct 2023
Novo Nordisk A/S NVO, +1.96% NOVO.B, +0.08% said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension. Ocedurenone is a pill that also has potential appl
How weight loss drugs could impact stocks
11:00am, Saturday, 14'th Oct 2023
Weight loss drugs, such as Novo Nordisk's (NVO) Ozempic and Wegovy, continue to grow in popularity. With many brand and retailer CEOs signaling the hit to snack food sales, how will these drugs impact
1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs
10:23am, Saturday, 14'th Oct 2023
Ozempic and Wegovy have soared in popularity because of their ability to help people lose weight. Some recent reports, however, have described several potential side effects of concern.
Novo Nordisk Boosts Its Guidance on Demand for Its Weight-Loss Drugs, Again
05:05pm, Friday, 13'th Oct 2023
Novo Nordisk (NVO) boosted its guidance for the second time in two months as demand soars for its diabetes treatments, Ozempic and Wegovy. American depositary receipts (ADRs) of Novo Nordisk rose clos
Novo Nordisk raises full-year sales guidance due to Ozempic
04:59pm, Friday, 13'th Oct 2023
Novo Nordisk (NVO) shares are up on the last trading day of the week as the company raised its full-year sales and operating profit citing U.S. sales from GLP-1 drugs Wegovy and Ozempic. Yahoo Finance
Why Novo Nordisk Stock Raced Higher Today
04:56pm, Friday, 13'th Oct 2023
The Danish pharmaceutical developer updated its 2023 guidance. It raised its projected growth rates for both sales and operating profit.
